RxDoctor Payments Data

Melynda Brown, PA

Physician Assistant · Fort Myers, FLNPI 1851678106

Payments from drug & device makers

$5,799in general payments, 2019–2025

Across 179 payments — averaging $32.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Saluda Medical Americas, Inc.$1K
  • Collegium Pharmaceutical, Inc.$1K
  • Boston Scientific$760
  • AbbVie$315
  • Medtronic$306
  • Biohaven Pharmaceuticals, Inc.$306
  • plus $2K from 29 others

What the payments were for

  • Travel & lodging$4728%
  • Food & beverage$5,32792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,799 in reported general payments places this provider in the 90th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$204,333
Medicare patients
669
Services billed
2,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate24$47,186
RelistorMethylnaltrexone Bromide18$43,159
UbrelvyUbrogepant16$24,211
Lidocaine111$22,319
MovantikNaloxegol Oxalate22$12,066
Diclofenac Sodium113$10,425
Gabapentin403$9,735
Baclofen165$4,110
Celecoxib75$3,996
Methocarbamol99$3,485
Tizanidine Hcl149$3,451
Cyclobenzaprine Hcl85$2,874
Duloxetine Hcl90$2,233
Amitriptyline Hcl27$1,032
Ibuprofen30$973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$209$47,18624 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$58$43,15918 claims
AbbVieUbrelvy$315$24,21116 claims
Redhill Biopharma Inc.Movantik$89$12,06622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →